Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(10): 687-691
DOI: 10.1590/0004-282X20170121
Article

MOG-IgG associated optic neuritis is not multiple sclerosis

Neurite óptica associada ao MOG-IgG não é esclerose múltipla
Bruna Klein da Costa   *
1   Pontifícia Universidade Católica do Rio Grande do Sul, Faculdade de Medicina, Hospital São Lucas, Serviço de Neurologia, Porto Alegre RS, Brasil
2   Instituto do Cérebro do Rio Grande do Sul, Porto Alegre RS, Brasil
,
Giordani Rodrigues dos Passos   *
1   Pontifícia Universidade Católica do Rio Grande do Sul, Faculdade de Medicina, Hospital São Lucas, Serviço de Neurologia, Porto Alegre RS, Brasil
2   Instituto do Cérebro do Rio Grande do Sul, Porto Alegre RS, Brasil
,
Jefferson Becker
1   Pontifícia Universidade Católica do Rio Grande do Sul, Faculdade de Medicina, Hospital São Lucas, Serviço de Neurologia, Porto Alegre RS, Brasil
2   Instituto do Cérebro do Rio Grande do Sul, Porto Alegre RS, Brasil
,
Douglas Kazutoshi Sato
1   Pontifícia Universidade Católica do Rio Grande do Sul, Faculdade de Medicina, Hospital São Lucas, Serviço de Neurologia, Porto Alegre RS, Brasil
2   Instituto do Cérebro do Rio Grande do Sul, Porto Alegre RS, Brasil
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Autoantibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been reported in patients with inflammatory central nervous system disorders including isolated optic neuritis (ON). We compared our MOG-IgG ON patients with multiple sclerosis (MS) patients presenting with ON. Methods and results: Among the total of 38 patients with optic neuropathies, six patients with isolated ON were MOG-IgG positive and eight patients with ON fulfilled the diagnostic criteria for MS. All MS patients were negative for MOG-IgG using a cell-based assay. When compared with the MS group, the MOG-IgG patients were older (mean 47 years), more frequently male (ratio 2:1) and had a higher frequency of bilateral and/or recurrent ON. The brain magnetic resonance imaging of all MOG-IgG positive patients was normal or had only unspecific white matter T2 lesions. Conclusion: These findings suggest that MOG-IgG is a biomarker of an inflammatory demyelinating CNS disease distinct from MS.

RESUMO

Autoanticorpos contra a glicoproteína da mielina do oligodendrócito (MOG-IgG) têm sido descritos em pacientes com neurite óptica (NO) isolada, entre outras doenças inflamatórias do sistema nervoso central. Comparamos os nossos pacientes com NO MOG-IgG positivos com pacientes com NO associada a esclerose múltipla (EM). Materias e métodos: De um total de 38 pacientes com neuropatia óptica, seis foram MOG-IgG positivos e oito preencheram critérios diagnósticos para EM. Todos os pacientes com EM foram negativos para MOG-IgG (ensaio baseado em células). Quando comparados ao grupo com EM, os pacientes MOG-IgG positivos apresentam idade mais avançada (mediana de 47 anos) e tiveram uma frequência maior de NO bilateral e/ou recorrente. Houve predomínio masculino (relação 2:1). A ressonância magnética de encéfalo de todos os pacientes MOG-IgG positivos foi normal ou demonstrou apenas lesões inespecíficas em T2. Conclusão: Nossos achados sugerem que o MOG-IgG é um biomarcador de doença desmielinizante diferente da EM.

Keywords:

optic neuritis - multiple sclerosis - myelin oligodendrocyte glycoprotein - autoantibodies - demyelinating diseases

Palavras-chave:

neurite óptica - esclerose múltipla - glicoproteína mielina-oligodendrócito - autoanticorpos - doenças desmielinizantes

* Both authors contributed equally to this work.




Publication History

Received: 09 July 2017

Accepted: 13 July 2017

Article published online:
04 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7(1):185-217. https://doi.org/10.1146/annurev-pathol-011811-132443
  • 2 Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(Pt 3):393-9. https://doi.org/10.1093/brain/120.3.393
  • 3 Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12. https://doi.org/10.1016/S0140-6736(04)17551-X
  • 4 Mayer MC, Meinl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disorder. 2012;5(3):147-59. https://doi.org/10.1177/1756285611433772
  • 5 Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9(8):455-61. https://doi.org/10.1038/nrneurol.2013.118
  • 6 Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FMH, Takahashi T et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-81. https://doi.org/10.1212/WNL.20170121201701210101
  • 7 Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. https://doi.org/10.1212/WNL.20170121201701211729
  • 8 Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
  • 9 Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e131. https://doi.org/10.1212/NXI.20170121201701210131
  • 10 Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014;1(4):e40. https://doi.org/10.1212/NXI.20170121201701210040
  • 11 Nakajima H, Motomura M, Tanaka K, Fujikawa A, Nakata R, Maeda Y et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4):e007766. https://doi.org/10.1136/bmjopen-2015-007766